- Management of GCC Commercial operations.- Pipeline management.- Distributors Relationship Management.- Business Development Projects for complimentary brands (In and Out-Licensing & acquisition projects).- Driving GCC Growth Strategy.- Market access & Reimbursement.- P&L accountability.- GCC Strategy.Key Accomplishments:- Asset Transfer from AstraZeneca to Luye Pharma in 6 GCC Markets.- Set Up Luye Pharma Regional Distribution Hub.-Appointment of Luye Pharma Business Partners in 6 GCC Markets.- Increase profitability of Luye Pharma Asset in GCC.

Key Responsibilities:• MENA region business model setup, access strategy & priority markets launches.• Partners selection and appointment of the commercial network in MENA region.• Techdow product access in MENA region tender and retail market.Key Accomplishments:- Appointment of business partners in Saudi, UAE and Kuwait.- Registration of Clexane Biosimilar in Saudi and UAE - fast track registration.

Key Accomplishments:• Set up Kyowa Kirin Regional Office in Middle East – FZ LLC.• Appointment of Kyowa Kirin Distributors network in GCC.• Recruitment of the senior leadership team.• Repatriation of Amgen supportive care portfolio (Neupogen, Neulastim and OBI) in GCC, business size 20 Million USD, Drafting Transfer Service Agreement with Amgen, Distributors assessment, termination and appointing new partners, Preparing the markets for new Launches, Managing price references during Marketing Authorization Transfers, Managing inventory and bridging stocks and supply chain complexity.• Tender management in GCC, taking decisions on tender participation, pricing strategy and tenders control.• Pricing Strategy for Neupogen, Neulastim and OBI in GCC for 5 years.

Key Accomplishments:• Outstanding results for Concordia which translated into +50% EBIT overachievement in 2015 and 2016 through different and smart strategies,1. Freight cost smart control which resulted in 4% cost saving.2. FOC control for the strategic products which improved the EBIT by 5%.3. Portfolio prioritization and focusing on high profit margin products which lead to an EBIT increase by 14%.4. Head count synergies which resulted in 4%5. Bad debts recovery– Over 3 M USD.• Secure Concordia business continuity in Saudi market by:1. Appointment of a non-exclusive distributor (one of the top 5 distributors in Saudi market) resulted in:(a) Improve the account receivables from 180 days in average to 90 days.(b) Strategic items availability and avoiding the historical stock rupture by building a strategic stock which results in smooth in-market sales.2. 3 million USD bad debts recovery from the distributors without using the court option.• Over achieving 2016 budgeted revenues by 20% through:1. 30% GR in the in-market sales for key strategic products in the private market.2. Excellent tender management which resulted in 150% GR of the awarded items value.

Key Accomplishments:• Increase Takeda PPI MS in Proton Pump Inhibitor (PPI) segment by 3% in Year 1 after launching Takeda 2nd PPI to the market in UAE through a very successful co-positioning strategy resulted in increase on Takeda PPI MS to be 21%

Key Accomplishments:• Increase EBIT by 7% through restructuring the sales force (lines up) to create more synergies and accommodate more products.• Revenue growth by 2% through in-license of the GI products that fit with Takeda PPI portfolio.

Key Accomplishments:• Daxas successful launch in Lebanon 2011, UAE 2012 achieving 6% & 3% respectively MS in year 1 in COPD defined market.• Omnaris Successful launch in UAE 2012 and achieving 10% MS in year 1.

Key Accomplishments:• Increase Controloc (Takeda PPI) by 4 points MS to maintain its leading position in PPI market by 17.8% MS through smart marketing strategies in a very crowded and highly genericized market.• Alvesco launch in Egypt 2009 and achieve 14% in the inhaled steroid segment in year 1.

Key Accomplishments:• Formulary enlisting of both Nexium and Symbicort in Saudi Aramco, Armed Forces Hospitals.